Neurological update: MOG antibody disease

Area of Science:

• Neuroimmunology
• Neurology

Background:

• Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) is a recognized neurological entity.
• It presents with specific clinical and paraclinical features, often involving optic neuritis, and affects individuals across all age groups, with a median onset in the fourth decade.

Purpose of the Study:

• To outline the diagnostic criteria and management strategies for MOG antibody disease.
• To differentiate MOG-AD from other neuroinflammatory conditions like multiple sclerosis and neuromyelitis optica.

Main Methods:

• Utilizing clinical presentation, paraclinical features, and validated cell-based MOG antibody testing for diagnosis.
• Employing MRI characteristics to distinguish MOG-AD from other neuroinflammatory disorders.
• Reviewing observational data for treatment efficacy.

Main Results:

• Optic neuritis is the most common presenting phenotype, and transverse myelitis at onset predicts worse long-term outcomes.
• MOG antibody testing shows improved sensitivity and specificity, crucial for accurate diagnosis.
• MRI findings aid in differentiating MOG-AD, and cerebrospinal fluid oligoclonal bands are infrequent.

Conclusions:

• MOG-AD requires specific diagnostic approaches, including validated MOG antibody testing and characteristic MRI findings.
• Early diagnosis and appropriate treatment, including high-dose steroids, plasma exchange, and immunosuppressants, are vital for managing MOG-AD and improving patient outcomes.